University Hospital Helsinki
Welcome,         Profile    Billing    Logout  
 5 Trials 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Strbian, Daniel
NCT02864953 / 2017-004854-41: Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Terminated
3
535
Europe, Canada, Japan, US, RoW
BIIB093, glibenclamide, glibenclamide intravenous (IV), glyburide, CIRARA, Placebo
Remedy Pharmaceuticals, Inc.
Brain Edema, Stroke, Acute
08/23
08/23
NCT05814523: To Evaluate the Efficacy, Safety, and Tolerability of Intravenous Ganaxolone Added to Standard of Care in Refractory Status Epilepticus (RSE)

Withdrawn
3
70
Europe, RoW
Ganaxolone, Placebo, Standard of care
Marinus Pharmaceuticals
Refractory Status Epilepticus
08/24
08/24
DISTAL, NCT05029414: EnDovascular Therapy Plus Best Medical Treatment (BMT) Versus BMT Alone for MedIum VeSsel Occlusion sTroke

Active, not recruiting
N/A
543
Europe, RoW
Endovascular Therapy
University Hospital, Basel, Switzerland, Swiss National Fund for Scientific Research, Stryker Neurovascular, Penumbra Inc., Medtronic, Phenox GmbH, Rapid Medical, Gottfried und Julia Bangerter-Rhyner-Stiftung
Acute Ischemic Stroke
10/24
06/25

Download Options